Oncol Case Rep J | Volume 5, Issue 2 | Case Report | Open Access

Targeting the Oncogenic Driver BRAF V600E Mutation in Metastatic Symptomatic Multiagent Refractory Papillary Thyroid Cancer Done Successfully Using Dabrafenib and Trametinib: Case Report and Literature Review

Morrison DG^*, Castellon C, Cuadras A, Ortega A and Lopez J

Department of Hematology and Oncology, The Oncology Institute of Hope and Innovation, USA

^*Correspondance to: Morrison DG 

Abstract

Radioactive iodine refractory metastatic papillary thyroid cancer is usually managed with lenvima. Other small molecule inhibitors are used when it fails. Many papillary thyroid cancers have BRAF V600 mutations. We report the successful use of dabrafenib and trametinib after multiple agents have failed. A unique tumor flare response was observed.

Keywords:

BRAF V600; Thyroid Cancer; Drug

Citation:

Morrison DG, Castellon C, Cuadras A, Ortega A, Lopez J. Targeting the Oncogenic Driver BRAF V600E Mutation in Metastatic Symptomatic Multiagent Refractory Papillary Thyroid Cancer Done Successfully Using Dabrafenib and Trametinib: Case Report and Literature Review. Oncol Case Report J. 2022; 5(2): 1048..